PT1750683E - Formulações de libertação sustida - Google Patents

Formulações de libertação sustida

Info

Publication number
PT1750683E
PT1750683E PT57423154T PT05742315T PT1750683E PT 1750683 E PT1750683 E PT 1750683E PT 57423154 T PT57423154 T PT 57423154T PT 05742315 T PT05742315 T PT 05742315T PT 1750683 E PT1750683 E PT 1750683E
Authority
PT
Portugal
Prior art keywords
sustained release
release formulations
formulations
sustained
release
Prior art date
Application number
PT57423154T
Other languages
English (en)
Portuguese (pt)
Inventor
Merrill S Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT1750683E publication Critical patent/PT1750683E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT57423154T 2004-04-23 2005-04-25 Formulações de libertação sustida PT1750683E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23

Publications (1)

Publication Number Publication Date
PT1750683E true PT1750683E (pt) 2013-01-25

Family

ID=34967842

Family Applications (1)

Application Number Title Priority Date Filing Date
PT57423154T PT1750683E (pt) 2004-04-23 2005-04-25 Formulações de libertação sustida

Country Status (15)

Country Link
US (2) US7323169B2 (2)
EP (1) EP1750683B1 (2)
JP (3) JP5036533B2 (2)
KR (1) KR101201638B1 (2)
CN (2) CN1997356A (2)
AU (1) AU2005237542B2 (2)
CA (1) CA2563185C (2)
DK (1) DK1750683T3 (2)
ES (1) ES2400687T3 (2)
IL (1) IL178596A (2)
PL (1) PL1750683T3 (2)
PT (1) PT1750683E (2)
SI (1) SI1750683T1 (2)
WO (1) WO2005105057A1 (2)
ZA (1) ZA200609401B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750683B1 (en) * 2004-04-23 2013-01-09 Amgen Inc. Sustained release formulations
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
CA2642632A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
US20090173876A1 (en) * 2006-07-21 2009-07-09 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
EP2709711B8 (en) 2011-05-18 2017-03-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
HK1203384A1 (en) * 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
WO2018226383A1 (en) * 2017-06-07 2018-12-13 Egy-Nano Pharma, Lp Oral prolonged drug delivery platforms
WO2020027882A1 (en) 2018-08-03 2020-02-06 Nectero Medical, Inc. Purified pentagalloyl glucose and devices for delivery
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN119326891B (zh) * 2024-10-31 2025-07-01 中国人民解放军空军军医大学 Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
AU8578498A (en) * 1997-07-23 1999-02-16 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
CA2325983C (en) * 1998-04-20 2009-02-17 Genzyme Corporation Drug delivery of proteins from polymeric blends
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
WO2001032218A1 (en) 1999-11-01 2001-05-10 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
US6759064B2 (en) * 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
WO2004012522A1 (en) 2002-07-26 2004-02-12 Dsm Ip Assets B.V. Compositions comprising lactoferrin
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
EP1750683B1 (en) * 2004-04-23 2013-01-09 Amgen Inc. Sustained release formulations

Also Published As

Publication number Publication date
US7323169B2 (en) 2008-01-29
WO2005105057A1 (en) 2005-11-10
CA2563185A1 (en) 2005-11-10
US20050271722A1 (en) 2005-12-08
DK1750683T3 (da) 2013-04-15
PL1750683T3 (pl) 2013-05-31
HK1200092A1 (en) 2015-07-31
EP1750683A1 (en) 2007-02-14
EP1750683B1 (en) 2013-01-09
JP2007534698A (ja) 2007-11-29
ZA200609401B (en) 2008-05-28
AU2005237542A1 (en) 2005-11-10
CN1997356A (zh) 2007-07-11
AU2005237542B2 (en) 2009-12-17
IL178596A0 (en) 2007-02-11
JP5829870B2 (ja) 2015-12-09
KR101201638B1 (ko) 2012-11-15
JP2012046520A (ja) 2012-03-08
HK1103023A1 (en) 2007-12-14
KR20070026457A (ko) 2007-03-08
ES2400687T3 (es) 2013-04-11
JP5036533B2 (ja) 2012-09-26
US7732399B2 (en) 2010-06-08
CA2563185C (en) 2010-04-20
US20070292506A1 (en) 2007-12-20
CN103920162A (zh) 2014-07-16
CN103920162B (zh) 2017-07-11
JP2012036194A (ja) 2012-02-23
SI1750683T1 (sl) 2013-04-30
IL178596A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
IL184460A0 (en) Sustained release pharmaeutical formulations
IL178596A0 (en) Sustained release formulations
GB2424581B (en) Formulations
IL181265A0 (en) Stabilizing formulations
GB0406819D0 (en) Controlled release compositions
IL188964A0 (en) Sustained drug release composition
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
ZA200707654B (en) Formulations
PL2402005T3 (pl) Formulacje nalbufiny o przedłużonym uwalnianiu
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1951693A4 (en) SOLID FORMULATIONS
IL177328A0 (en) Controlled release formulations
GB0406048D0 (en) Drug formulations
IL179208A0 (en) Intereferon formulations
GB0417248D0 (en) Formulations
GB0417226D0 (en) Formulations
GB0426294D0 (en) Novel formulations
GB0426292D0 (en) Novel formulations
GB0420817D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations
GB0427249D0 (en) Novel formulations
GB0420818D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations